Lv2
170 积分 2025-05-29 加入
Targeting protein disorder: the next hurdle in drug discovery
5小时前
待确认
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation
21天前
已完结
The changing landscape of medicinal chemistry optimization
21天前
已完结
Time-resolved fluorescent proteins expand fluorescent microscopy in temporal and spectral domains
1个月前
已完结
Kinase inhibitors: the road ahead
1个月前
已完结
Fifty years of monoclonals: the past, present and future of antibody therapeutics
1个月前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
1个月前
已完结
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
1个月前
已完结
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
2个月前
已完结
Unleashing the Potential: Designing Antibody-Targeted Lipid Nanoparticles for Industrial Applications with CMC Considerations and Clinical Outlook
2个月前
已完结
皖公网安备34019202002308
